0001209191-23-020744.txt : 20230323 0001209191-23-020744.hdr.sgml : 20230323 20230323161716 ACCESSION NUMBER: 0001209191-23-020744 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230323 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wagner Paul A. CENTRAL INDEX KEY: 0001612842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 23756446 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-23 0 0001419041 Forte Biosciences, Inc. FBRX 0001612842 Wagner Paul A. C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 1 1 0 0 See Remarks 0 Restricted Stock Units 2023-03-23 4 A 0 500000 0.00 A Common Stock 500000 500000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. CEO, President, Secretary and Chair of the Board /s/ Paul A. Wagner, Ph.D 2023-03-23